SIGA SIGA TECHNOLOGIES INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1010086 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-69.6%
TTM net income YoY-99.1%
TTM EPS YoY-99.0%
Revenue 3-yr CAGR14.6%
Net income 3-yr CAGR—
Margins
Gross margin54.0%
Operating margin-14.2%
Net margin1.3%
FCF margin-22.1%
EBITDA margin-13.0%
Returns
ROE0.4%
ROA0.3%
ROIC (approx.)-15.0%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets5.4%
Debt / equity0.00x
Current ratio24.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-16.81x
Accruals ratio6.0%
Payout ratio6,325.2%
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $94.57M | $138.72M | $139.92M | $110.78M | $133.67M |
| Cost of revenue | $29.70M | $31.29M | $17.83M | $10.43M | $16.60M |
| Gross profit | $64.87M | $107.43M | $122.09M | $100.34M | $117.07M |
| R&D expense | $19.96M | $12.31M | $16.43M | $22.53M | $9.94M |
| SG&A expense | $21.21M | $25.14M | $22.04M | $35.12M | $18.03M |
| Operating income | $23.70M | $69.98M | $83.62M | $42.70M | $89.09M |
| Interest expense | — | — | — | $0 | $0 |
| Pretax income | $30.38M | $76.07M | $87.78M | $44.13M | $89.31M |
| Income tax | $7.10M | $16.86M | $19.71M | $10.23M | $19.86M |
| Net income | $23.28M | $59.21M | $68.07M | $33.90M | $69.45M |
| EBITDA | $24.26M | $70.52M | $84.16M | $43.22M | $89.62M |
| EPS (basic) | 0.33 | 0.83 | 0.95 | 0.46 | 0.92 |
| EPS (diluted) | 0.32 | 0.82 | 0.95 | 0.46 | 0.91 |
| Dividends declared per share | 0.60 | 0.60 | 0.45 | 0.45 | — |
| Weighted avg. shares (diluted) | 71.87M | 71.91M | 71.68M | 73.55M | 76.40M |
| Balance sheet | |||||
| Cash & equivalents | $154.97M | $155.40M | $150.15M | $98.79M | $103.14M |
| Receivables | $3.26M | $21.17M | $21.13M | $45.41M | $83.65M |
| Inventory | $49.05M | $49.56M | $64.22M | $39.27M | $19.51M |
| Current assets | $212.86M | $231.04M | $238.99M | $185.79M | $208.75M |
| PP&E, net | $1.09M | $1.30M | $1.33M | $1.85M | $2.37M |
| Goodwill | $898,334 | $898,334 | $898,334 | $898,334 | $898,334 |
| Total assets | $219.47M | $244.34M | $254.35M | $195.04M | $214.73M |
| Current liabilities | $17.99M | $25.33M | $54.12M | $21.52M | $30.49M |
| Total liabilities | $20.65M | $28.53M | $57.49M | $24.88M | $40.41M |
| Shareholders' equity | $198.82M | $215.80M | $196.86M | $170.16M | $174.31M |
| Shares outstanding | 71.61M | 71.40M | 71.09M | 72.68M | 73.54M |
| Cash flow statement | |||||
| Operating cash flow | $43.47M | $48.76M | $94.80M | $41.61M | $11.49M |
| Capital expenditure | $355,009 | $42,450 | $21,686 | $0 | $50,620 |
| Free cash flow | $43.12M | $48.72M | $94.78M | $41.61M | $11.44M |
| Investing cash flow | -$355,009 | -$42,450 | -$21,686 | $0 | -$50,620 |
| Financing cash flow | -$43.55M | -$43.46M | -$43.42M | -$45.96M | -$26.20M |
| Depreciation & amortization | $562,607 | $538,421 | $538,293 | $517,643 | $522,368 |
| Stock-based compensation | $3.68M | $3.64M | $2.05M | $1.78M | $1.27M |
| Dividends paid | $43.12M | $42.67M | $32.14M | $32.94M | $0 |
| Share buybacks | $0 | $0 | $11.07M | $13.01M | $26.02M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.